Skip to content

Study · Non-randomized trial · 1980

3 results

Comparison of a low and high dose ACTH gel in the treatment of hay fever.

Parr EJ, Davies BH

Clinical allergy1 Mar 1980

PMID6248266 (opens in a new tab)DOI10.1111/j.1365-2222.1980.tb02097.x (opens in a new tab)PepBankPUB-06248266
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In hay fever patients, symptoms during peak pollen challenge were lower with 200 iu Acthar gel than with 80 iu.

    In plain wordsIn hay fever patients, 200 iu Acthar gel reduced symptoms more than 80 iu during peak pollen challenge.

    Peptide
    ACTH (corticotropin)
    Outcome
    DecreaseHay fever symptoms during peak pollen challenge
    Study

    n: not reported in source

    Comparator
    80 iu Acthar gel
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    200 iuAs given in this study (human).

    Source sentences

    Summary
    The present data show that in fourteen patients treated with 200 iu Acthar gel, hay fever symptoms were less during the period of peak pollen challenge during June, than those experienced by an equivalent group treated with 80 iu.
  2. 02HumanNon-randomized trialEfficacy outcome

    Among the seven worst hay fever sufferers in both groups, symptoms differed significantly between 200 iu and 80 iu Acthar gel (P=0.033).

    In plain wordsIn the worst hay fever sufferers, 200 iu Acthar gel reduced symptoms more than 80 iu.

    Peptide
    ACTH (corticotropin)
    Outcome
    DecreaseSymptoms in worst sufferers
    Study

    n: not reported in source

    Comparator
    80 iu Acthar gel
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    200 iuAs given in this study (human).

    Measurements

    P value
    0.033
    symptom comparison

    Source sentences

    Summary
    Analysis of the data showed that in the seven worst sufferers in both groups the difference between treatments was statistically significant (P=0.033, estimated by analysis of covariance of the symptom scores over the period of peak pollen challenge).
    1 context sentence
    Summary · context
    The present data show that in fourteen patients treated with 200 iu Acthar gel, hay fever symptoms were less during the period of peak pollen challenge during June, than those experienced by an equivalent group treated with 80 iu.
  3. 03HumanNon-randomized trialSafety outcome

    In hay fever patients, neither Acthar gel dose group had serious side effects.

    In plain wordsIn hay fever patients, neither Acthar gel dose group had serious side effects.

    Peptide
    ACTH (corticotropin)
    Outcome
    Not applicableSerious side effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    200 iu or 80 iuAs given in this study (human).

    Source sentences

    Summary
    No serious side effects were noted in patients from either group.
    1 context sentence
    Summary · context
    The present data show that in fourteen patients treated with 200 iu Acthar gel, hay fever symptoms were less during the period of peak pollen challenge during June, than those experienced by an equivalent group treated with 80 iu.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.